miR-23b在NSCLC患者血清中的表达及其预后评估价值分析

The Expression Level of miR-23b in Serum of Patients with Non-small Cell Lung Cancer and Its Prognostic Value

目的观察miR-23b在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清中的表达水平及其对预后的评估价值。方法选取我院2012年1月—2014年12月收治的86例NSCLC作为观察组,另选取同期于我院体检身体健康者60例作为对照组,分析两组血清miR-23b表达情况及观察组患者随访3年后的生存情况,并分析影响NSCLC患者预后的相关因素。结果 (1)观察组患者血清miR-23b水平显著高于对照组,且观察组患者血清miR-23b高表达率为74.42%显著高于对照组的20.00%,差异均有统计学意义(P<0.01);(2)miR-23b高表达患者生存率明显低于miR-23b低表达患者,差异有统计学意义(χ~2=7.184,P=0.007);(3)病理分期过高、肿瘤存在远处转移、肿瘤存在淋巴结转移、肿瘤组织分化程度较低和miR-23b高表达为NSCLC患者预后的独立危险因素。结论 miR-23b在NSCLC患者血清中表达升高,且病理分期过高、肿瘤存在远处转移、肿瘤存在淋巴结转移、肿瘤组织分化程度较低和miR-23b高表达为NSCLC患者预后的独立危险因素,血清miR-23b可作为临床评估NSCLC患者预后的有效指标。

Objective To observe the expression level of mir-23b in the serum of patients with non-small cell lung cancer(NSCLC)and its prognostic value.Methods Eighty-six patients with NSCLC who were admitted and treated in our hospital between January 2012 and December 2014 were selected as observation group and 60 healthy people who underwent physical examination in our hospital during the same period served as control group.The expression of serum miR-23 b in the two groups,the survival of patients in the observation group after 3-year follow-up,and the related factors affecting the prognosis of patients with NSCLC were analyzed.Results①The serum mir-23b level of the observation group was significantly higher than that of the control group,and the high expression rate of mir-23b(74.42%)in the observation group was remarkably higher than that(20.00%)of the control group,with statistically significant differences(P<0.01).②Survival rate of patients with high mir-23b expression was significantly lower,as compared with those with low mir-23b expression,and the difference was statistically significant(χ2=7.184,P=0.007).③High pathological stage,distant metastasis of tumor,lymph node metastasis of tumor,low degree of tumor differentiation and high expression of mir-23b were independent risk factors for prognosis of NSCLC patients.Conclusion The increased expression of mir-23b in the serum of NSCLC patients,high pathological stage,distant metastasis of the tumor,lymph node metastasis,low degree of tumor differentiation,and the high expression of mir-23b are independent risk factors for the prognosis of NSCLC patients.The serum mir-23b can be used as an effective indicator for clinical evaluation of the prognosis of NSCLC patients.